About Apyx Medical Corporation - Common Stock (APYX)
Apyx Medical Corp is a medical technology company focused on developing innovative solutions for surgical applications. The company specializes in advanced energy-based devices, particularly those that utilize its proprietary Renu™ technology, which enables precise and controlled tissue dissection and coagulation. Apyx Medical's products are designed to enhance surgical outcomes by improving the safety and effectiveness of procedures, while also providing surgeons with state-of-the-art tools that facilitate greater control and efficiency during operations. Through continuous innovation, Apyx aims to meet the evolving needs of healthcare professionals in various surgical specialties. Read More
As November 20, 2025, unfolds, global financial markets present a landscape of intriguing contrasts, marked by the persistent, transformative power of artificial intelligence and a growing undercurrent of investor caution. While select sectors and geographies celebrate robust growth fueled by technological advancements and strong earnings, broader market sentiment in key
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Apyx Medical Q3 2025 earnings beat expectations with a 50% EPS surprise and strong revenue. Stock surges on successful AYON Body Contouring System launch.
APYX Medical Corp reported Q2 2025 results with revenue of $11.37M, missing estimates, but a narrower EPS loss of -$0.09. Stock shows muted reaction amid commercial expansion plans.
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the journal, Plastic and Reconstructive Surgery—Global Open, featuring the results of study which compared the use of Renuvion’s Helium Plasma Technology to InMode’s Bipolar RF System (“Bipolar RF”) following liposuction or body contouring procedures.
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024.
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th.
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024.
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024.
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th.
Apyx® Medical Corporation (NASDAQ:APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.77% to 39,814.95 while the NASDAQ rose 0.25% to 16,410.54. The S&P 500 also rose, gaining, 0.38% to 5,244.72.
